Articles from Tenpoint Therapeutics, Ltd.

Tenpoint Therapeutics, Ltd. (“Tenpoint”), a global, clinical-stage biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announces that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for BRIMOCHOL™ PF for the treatment of presbyopia. The FDA has set a Prescription Drug User Fee Act (PDUFA) date of January 28, 2026, for BRIMOCHOL™ PF. The FDA noted that it is not planning to hold an advisory committee meeting to discuss this application.

Tenpoint Therapeutics, Ltd. (“Tenpoint”), a global, clinical-stage biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced the appointment of Melissa Epperly as Chief Financial Officer (CFO). In this role, Epperly will oversee Tenpoint’s financial strategy, capital markets activities, and operational finance functions as the company prepares for the potential U.S. launch of BRIMOCHOL™ PF, its lead candidate for the treatment of presbyopia.

Tenpoint Therapeutics, Ltd. (“Tenpoint”), a global, clinical-stage biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced that Henric Bjarke, Chief Executive Officer of Tenpoint Therapeutics, will participate in one-on-one meetings at the virtual Citi Biotech Private Access Day on April 24.

Tenpoint Therapeutics, Ltd. (“Tenpoint”), a global, clinical-stage biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for BRIMOCHOL™ PF for the treatment of presbyopia, an age-related near-vision loss condition impacting approximately two billion people globally and 128 million people in the United States.1

Tenpoint Therapeutics, Ltd. (“Tenpoint”), a global, clinical-stage biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced that the Company will participate in two upcoming investor conferences in April.